Dyax, Genzyme Phase II DX-88 data

DYAX and GENZ presented final results from the double-blind, placebo-controlled, dose-escalating EDEMA1 Phase II trial of

Read the full 163 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE